Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_assertion type Assertion NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_head.
- NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_assertion description "[In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_provenance.
- NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_assertion evidence source_evidence_literature NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_provenance.
- NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_assertion SIO_000772 21641636 NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_provenance.
- NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_assertion wasDerivedFrom befree-2016 NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_provenance.
- NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_assertion wasGeneratedBy ECO_0000203 NP899429.RAw29tnQ3cFb3ZH53x6mWxOQ3mWmd40H0fPk9anXnyIyI130_provenance.